CenExel's New CFO Hire Reveals an Aggressive Growth Playbook

DRAPER, Utah – June 18, 2026 – On the surface, CenExel's announcement of a new Chief Financial Officer is standard corporate procedure. But a closer look at the appointment of Bethany Sensenig as CFO and Head of Strategy reveals a move that is anything but routine. It is a clear and calculated signal of the clinical research site network's ambition to aggressively scale its operations and consolidate its market position, likely fueled by the kind of private equity playbook Sensenig knows intimately.

This move is not an isolated event. It comes just one month after the company installed Sy Pretorius as its new Chief Executive Officer. The rapid, back-to-back placement of a new CEO and a strategically-minded CFO points to a company positioning itself for a period of intense transformation. CenExel's stated goal is to become the “largest site network of scale in the U.S.,” and with Sensenig’s appointment, the financial and strategic architecture for that campaign is now falling into place.

A New Guard for a New Campaign

The assembly of a new leadership team in such a compressed timeframe is rarely a coincidence. The installation of Pretorius in May, followed swiftly by Sensenig in June, suggests a deliberate overhaul designed to inject new vision and operational horsepower into the organization. This is not a simple changing of the guard; it is the strategic mobilization of an executive team built for a specific purpose: rapid, intelligent growth.

In a statement, CEO Sy Pretorius noted that Sensenig will play a “critical role in ensuring CenExel remains at the forefront of innovation, quality, and growth” as the clinical research landscape evolves. The key terms here are “innovation” and “growth.” In the hyper-competitive world of clinical trials, growth is not merely about adding more sites; it's about creating an integrated, efficient, and technologically advanced network that can deliver consistent, high-quality data for pharmaceutical sponsors. This requires significant capital, strategic acquisitions, and meticulous operational integration—all areas that fall squarely under the purview of a CFO who also serves as Head of Strategy.

Sensenig’s dual title is perhaps the most telling detail. It signifies that her role transcends traditional financial oversight. She is not just there to manage the books but to architect the financial strategy that will enable CenExel’s ambitious market-share grab. This fusion of finance and strategy is essential for any company embarking on a capital-intensive journey of expansion and acquisition, suggesting CenExel is preparing for precisely such a phase.

The Financial Architect for a PE Playbook

To understand the full weight of Sensenig’s appointment, one must examine her track record. Her nearly three decades in the biopharmaceutical sector are impressive, with a 13-year tenure at Biogen that saw her manage a P&L exceeding $1 billion. However, it is her more recent experience that provides the clearest window into CenExel’s strategy. Most recently, Sensenig served as CFO and Head of Operations at Radius Health, where she was instrumental in “scaling the PE-backed business.”

This is the critical piece of the puzzle. Radius Health was acquired by private equity firms Gurnet Point Capital and Patient Square Capital in a deal valued at nearly $890 million in 2022. Sensenig navigated the company through this post-acquisition phase, a period defined by intense pressure to optimize financial performance, drive commercial growth, and deliver returns for its new owners. Her success in that environment, which culminated in Radius Health’s merger with Paratek Pharmaceuticals in March 2026, makes her a specialist in value creation under private equity ownership. Her experience isn't just in finance; it's in the high-stakes world of leveraging capital for rapid scaling and strategic exits.

By hiring an executive with this specific skill set, CenExel is telegraphing its own financial trajectory. Whether it is currently backed by private equity or is positioning itself for a major investment, the company has brought in a leader who speaks the language of institutional investors and understands how to deploy their capital effectively. Sensenig’s background in executing deals worth over $2 billion across her career further underscores her capability to lead the large-scale M&A activity that will be necessary for CenExel to achieve its goal of becoming the largest U.S. site network.

The Race to Scale in Clinical Research

CenExel’s leadership moves are happening within the broader context of a clinical research industry undergoing massive consolidation. The fragmented landscape of independent research sites is increasingly giving way to large, integrated site networks. Pharmaceutical sponsors, under pressure to run faster, more complex, and more efficient clinical trials, prefer to partner with large-scale networks that can offer access to diverse patient populations, standardized procedures, and centralized contracting and data management.

In this environment, “scale” is the ultimate competitive advantage. It translates to operational efficiency, negotiating power, and the ability to invest in cutting-edge technology for patient recruitment and data collection. CenExel’s ambition is not just to be the biggest in terms of the number of locations, but the largest “of scale”—implying a focus on building a deeply integrated and operationally excellent organization that can outperform smaller, less coordinated rivals.

Achieving this requires a two-pronged approach: organic growth at its existing “Centers of Excellence” and an aggressive M&A strategy to acquire other sites and smaller networks. Both prongs are capital-intensive and fraught with complexity. This is why the choice of a new CEO and a strategy-focused CFO is so pivotal. They are the leaders who will be tasked with identifying acquisition targets, securing the necessary funding, and, most importantly, ensuring that newly acquired assets are successfully integrated into the CenExel system without sacrificing quality or efficiency. The company’s focus on “premium data, and integrated operational excellence” is a direct acknowledgment that successful scaling is about more than just a larger footprint; it is about building a better, more reliable platform for clinical development.